Biological
Cixutumumab clinical trials
Also written IMC-A12 and LY3012217.
- studies test it
- 40
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
- IMC-A12
- 35
Studies by the year they started
40 studies that test it; most in 2009 (13)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 12 |
| 2009 | 13 |
| 2010 | 7 |
| 2011 | 4 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 29
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 29
National Cancer Institute (NCI) (26) · Eli Lilly and Company (11) · M.D. Anderson Cancer Center (2) · University of Washington (1)
Often tested with
Tested in the same studies.
Temsirolimus (7) · Cetuximab (2) · Octreotide (2) · HhAntag691 (1) · Bevacizumab (1) · Temozolomide (1) · Everolimus (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses cixutumumab is read from its arms, and is right about nine times in ten.
Testing it · 40
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01142388Written as Cixutumumab
- A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive StageCompletedPhase 2National Cancer Institute (NCI)NCT00887159Written as Cixutumumab
- S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedPhase 1/2National Cancer Institute (NCI)NCT00617708Written as cixutumumab
- Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT00684983Written as Cixutumumab
- Preoperative Treatment With Cetuximab and/or IMC-A12CompletedPhase 2M.D. Anderson Cancer CenterNCT00957853Written as IMC-A12
- Cixutumumab in Treating Patients With Metastatic Melanoma of the EyeCompletedPhase 2National Cancer Institute (NCI)NCT01413191Written as Cixutumumab
- A Study in Non-Small Cell Lung CancerCompletedPhase 2Eli Lilly and CompanyNCT01232452Written as Cixutumumab
- A Study of Cixutumumab (IMC-A12) in Islet Cell CancerCompletedPhase 2Eli Lilly and CompanyNCT00781911Written as Cixutumumab
- Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01026623Written as Cixutumumab
- BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT01263782Written as Cixutumumab
- A Study of IMC-A12 in Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT01007032Written as Cixutumumab
- A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is AvailableCompletedPhase 1Eli Lilly and CompanyNCT00785538Written as IMC-A12
- Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedPhase 2National Cancer Institute (NCI)NCT01614795Written as Cixutumumab
- Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate CancerCompletedPhase 2Eli Lilly and CompanyNCT00520481Written as IMC-A12 (Cixutumumab)
- A Five-Tier, Open-Label Study of IMC-A12 in Advanced SarcomaCompletedPhase 2Eli Lilly and CompanyNCT00668148Written as IMC-A12 (cixutumumab)
- A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and BevacizumabTerminatedPhase 2Eli Lilly and CompanyNCT00845039Written as IMC-A12 (cixutumumab)
- Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT00699491Written as Cixutumumab
- Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedPhase 2National Cancer Institute (NCI)NCT00955305Written as Cixutumumab
- A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the LiverCompletedPhase 2Eli Lilly and CompanyNCT00906373Written as IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)
- A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy BeforeCompletedPhase 2Eli Lilly and CompanyNCT00870870Written as IMC-A12 (cixutumumab)
See all 40 studies that test cixutumumab →
Given in every arm · 3 — cixutumumab is usual care beside what is tested
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast CancerCompletedPhase 2Eli Lilly and CompanyNCT00728949Written as IMC-A12 (cixutumumab)
- Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR TherapyCompletedPhase 2Eli Lilly and CompanyNCT00503685Written as IMC-A12
- Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and NeckCompletedPhase 2Eli Lilly and CompanyNCT00617734Written as IMC-A12 (cixutumumab)
Codes
What other systems call cixutumumab · ClinicalTrials.gg INT005802
- MeSH (NLM) C557414cixutumumabConfirmed NLM, Wikidata
- UNII (FDA) 2285XW22DRCIXUTUMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3678806cixutumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79828CixutumumabOne source FDA
- DrugBank DB12250One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C557414 | cixutumumab | Confirmed NLM, Wikidata |
| UNII (FDA) | 2285XW22DR | CIXUTUMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3678806 | cixutumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79828 | Cixutumumab | One source FDA |
| DrugBank | DB12250 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.